Perspective's promising PRRT trial results and solid financial position make CATX stock an attractive long-term investment ...

Learn about the promising Monopar Therapeutics Inc. MNPR-101 treatment targeting solid tumors and how it aims to reduce ...

Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s ...

Adenosine deaminase 2 (ADA2) has been identified as a regulator of toll-like receptor 9 (TLR9) activation in response ...

The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 URO-901-3005 trial.

The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first ... that targets phosphoinostide 3 kinase ...

State Street Corp grew its position in Perspective Therapeutics, Inc. (NYSE:CATX – Free Report) by 119.6% in the third quarter, HoldingsChannel reports. The institutional investor owned 2,190,239 ...

Keymed Biosciences Inc. (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Application (the "sNDA") of ...

What drives differences in symptoms and treatment response in men and women with Parkinson’s disease? Simon Grant explains ...

Anifrolumab is under clinical development by AstraZeneca and currently in Phase II for Vitiligo. According to GlobalData, Phase II drugs for Vitiligo have a 42% phase transition success rate (PTSR) ...

Xiaomi Mi Mix Alpha is powered by a 1.8GHz octa-core Qualcomm Snapdragon 855+ processor that features 1 core clocked at 2.96GHz, 3 cores clocked at 2.42GHz and 4 cores clocked at 1.8GHz. It comes with ...